# A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

> **NCT03619850** · PHASE3 · RECRUITING · sponsor: **AMAG Pharmaceuticals, Inc.** · enrollment: 129 (estimated)

## Conditions studied

- Chronic Kidney Disease; Iron Deficiency Anemia

## Interventions

- **DRUG:** Ferumoxytol
- **DRUG:** Iron sucrose

## Key facts

- **NCT ID:** NCT03619850
- **Lead sponsor:** AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-13
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03619850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03619850, "A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03619850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*